Table 1 CRISPR-Cas9 applied in the adoptive therapy in clinical trials
From: CRISPR–Cas9 applications in T cells and adoptive T cell therapies
Target locus | Tumor | Antigen | References |
|---|---|---|---|
TCR PD1 | Pleural mesothelioma, ovarian carcinoma, pancreatic ductal adenocarcinoma | Mesothelin CAR | |
PD1 | r/r aggressive B cell non-Hodgkin’s lymphoma, r/r non-Hodgkin’s lymphoma | CD19 CAR | |
CD52 TRAC | r/r CD19-positive B cell acute lymphoblastic leukemia (B-ALL) | CD19 CAR | [126] |
TRAC CD52 | r/r acute lymphoblastic leukemia (r/r ALL) | CD19/CD22 CAR | [150] |
CD52 TCRβ CD7 | Acute lymphoblastic leukemia | CD7 CAR | [151] |
TRAC TRBC | Myeloma, non-small cell lung cancer, ovarian, breast | NeoTCRs | [110] |
TRAC TRBC PD1 | Refractory myeloma; metastatic sarcoma | NY-ESO-1(TCR-T) | [85] |
PD1 | Advanced non-small cell lung cancer | TIL | [152] |